Stock Attack -- A Complete Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack -- A Complete Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nancy who wrote (11852)	7/12/1998 9:57:00 PM
From: Sonki	Read Replies (1) of 42787

hi, thanks for the ibd article. last friday, imnx @closing bid size 9 ask size 4. two exchanges vol on july 65 was very high compare to total oi. i.e. each was like 224 and 245 while total oi was 600. i think u r on to something. and december 80 costs 3.xx i.e. people expect to make 100 roi on their options would expect that stock should be 86. look at the target below: ha ha ha. Immunex (IMNX) 63 1/4 -1: Adams Harkness initiates coverage of developer of immune system therapeutics to treat cancer with "buy" with a year-end price target of $86; new management has transformed the company to one with impressive developmental ability and marketing expertise; expects company to lose $0.16 in FY98, but earn $0.57 in FY99 and $3.70 a share in FY02..... on aprail 28 Immunex Corp. (IMNX) 63 11/16 +1 7/16: Salomon Smith Barney upgrades biopharmaceutical concern from "outperform" to "buy"..... March 26, 1998 Janney Montgomery Scot Coverage was initiated with a HOLD rating based on valuation. The 1998 and 1999 EPS estimates were projected at ($0.67) and $0.35, respectively. The company is poised to make the transition to a profitable, product-driven biotech company with the application to the FDA for approval of its rheumatoid arthritis drug, Enbrel, expected in the second quarter. Pending FDA approval, it is possible that the launch of the drug could take place before the end of the year.'

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next